SCHEMBL172736

SCHEMBL172736

CN(C)c1nc(-c2ccccc2O)nc2c1CCN(Cc1ccccc1)C2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRS3 P32247 1/20 0.48
ALDH1A1 P00352 3/20 0.46
MAPT P10636 2/20 0.46
TSHR P16473 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PARP1 P09874 1/20 0.44
TNKS2 Q9H2K2 1/20 0.44
PARP2 Q9UGN5 1/20 0.44
CFTR P13569 4/20 0.41
C5AR1 P21730 1/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
STARD3 Q14849 1/20 0.40
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
DRD4 P21917 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10150203 0.92 BRS3 (0.42) BRS3ALDH1A1MAPTTSHRL3MBTL1
SCHEMBL8298135 0.92 BRS3 (0.48) BRS3ALDH1A1MAPTTSHRL3MBTL1
SCHEMBL10150215 0.89 CLPP (0.41) BRS3ALDH1A1MAPTTSHRL3MBTL1
SCHEMBL8298136 0.88 C5AR1 (0.40) BRS3ALDH1A1MAPTTSHRL3MBTL1
SCHEMBL10150207 0.88 ALDH1A1 (0.47) BRS3ALDH1A1MAPTKMT2AMEN1
SCHEMBL10150209 0.88 SIGMAR1 (0.43) ALDH1A1MAPTKMT2AMEN1KDM4E
SCHEMBL10150213 0.87 TNF (0.43) BRS3ALDH1A1MAPTTSHRL3MBTL1
SCHEMBL8298127 0.85 ALDH1A1 (0.48) BRS3ALDH1A1MAPTTSHRPARP1
SCHEMBL22720441 0.84 KMT2A (0.49) ALDH1A1MAPTTSHRL3MBTL1PARP1
SCHEMBL10150191 0.82 KDM4E (0.44) ALDH1A1MAPTTSHRL3MBTL1C5AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663994-B1 TETRAHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMA (US) 2012-03-07 EP disclosed
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-7968545-B2 Compositions useful as inhibitors of voltage-gated ion channels VERTEX PHARMACEUTICALS INC. (US) 2011-06-28 US disclosed
US-7968545-B2 Compositions useful as inhibitors of voltage-gated ion channels VERTEX PHARMACEUTICALS INC. (US) 2011-06-28 US disclosed
WO-2005014558-A1 CONDENSED PYRAMIDINE COMPOUNDS AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS KCNQ1, KCNN2, KCNH3 BRS3 753/4885ALDH1A1 3086/4885MAPT 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.